Fluoxetine-induced sleep disturbance in depressed patients

Neuropsychopharmacology

Volumn 14, Issue 6, 1996, Pages 437-442

  Dorsey, Cynthia M ^a   Lukas, Scott E ^a   Cunningham, Steven L ^a  

^a MCLEAN HOSPITAL   (United States)

Author keywords

Arousals; Fluoxetine; Insomnia; Nocturnal mycolonus; PLMD

Indexed keywords

FLUOXETINE;

ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; EYE MOVEMENT; HUMAN; INSOMNIA; NONREM SLEEP; PRIORITY JOURNAL;

EID: 0030157914     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1016/0893-133X(95)00148-7     Document Type: Article

References (28)

1. Armitage R, Trivedi M, Rush J, Pechacek P, Cole D, Dunnam D (1994): Effects of fluoxetine on EOG and EMG activity during sleep and depression. Sleep Res 23:61
2. Askenasy JM, Yahr MD (1988): Is monoamine oxidase inhibitor induced myoclonus serotonergically mediated? J Neural Transm 72:67-76
3. Atlas Task Force, Christian Guillemenault, Chairman (1992): EEG arousals: Scoring rules and examples. A preliminary report from the Sleep Disorders Atlas Task Force of the American Sleep Disorders Association. Sleep 15(2):174-184
4. Casas M, Garcia-Ribera C, Alvarez E, Udina C, MaQueralto J, MaGrau J (1987): Myoclonic movements as a sideeffect of treatment with therapeutic doses of clomipramine. Int Clin Psychopharmacol 2:333-336
5. Coleman RM (1982): Periodic movements in sleep (nocturnal myoclonus) and restless legs syndrome. In Guilleminault C (ed), Sleeping and Waking Disorders: Indications and Techniques. Menlo Park, CA, Addison-Wesley, pp 265-295
6. Coleman RM, Roffwarg HP, Kennedy SV, et al. (1982): Sleepwake disorders based on a polysomnographic diagnosis - A national cooperative study JAMA 247:997-1003
7. Cooper GL (1988): The safety of fluoxetine: An update. Br J Psychiatry 153(suppl. 3):77-86
8. Diagnostic Classification Steering Committee, Thorpy MJ, Chairman (1990): International Classification of Sleep Disorders: Diagnostic and Coding Manual. Rochester, MN, American Sleep Disorders Association
9. Dorsey CM, Cunningham SL, Lukas SE, Winkelman JW, Richardson GS, Jones K (1992a): Fluoxetine induced eye movements during non-REM sleep. Sleep Res 21:55
10. Dorsey CM, Cunningham SL, Richardson GS, Lukas SE, Winkelman JW (1992b): Increased risk of periodic leg movements during sleep with use of fluoxetine. Sleep Res 21:56
11. Evans DL, Davidson J, Raft D (1982): Early and late side effects of phenelzine. J Clin Psychopharmacol 2(3):208-210
12. Forstl H, Pohlmann-Eden B (1990): Amplitudes of somatosensory evoked potentials reflect cortical hyperexcitability in antidepressant-induced rnyoclonus. Neurology 40:924-926
13. Garvey MJ, Tollefson GD (1987): Occurrence of myoclonus in patients treated with cyclic antidepressants. Arch Gen Psychiatr 44:269-272
14. Guilleminault C, Raynal D, Weitzman ED, Dement WC (1975): Sleep-related periodic myoclonus in patients complaining of insomnia. Trans Am Neurol Assoc 100:19-22
15. Hamilton M (1969): A rating scale for depression. J Neurol Neurosurg Psychiatr 23:56-62
16. Keck PE, Hudson JI, Dorsey CM, Campbell PI (1991): Effect of fluoxetine on sleep [letter]. Biol Psychiatr 29:618-619
17. Lippmann S, Moskovitz R, O'Tuama L (1977): Tricyclic-induced myoclonus. Am J Psychiatr 134(1):90-91
18. Myers BA, Klerman GL, Hartmann E (1986): Nocturnal cataclysms with myoclonus: A new side effect of clomipramine. Am J Psychiatr 143(11):1490-1491
19. Noble J, Matthew H (1969): Acute poisoning by tricyclic antidepressants: Clinical features and management of 100 patients. Clin Toxicol 2:403-421
20. Rechtschaffen A, Kales AA (1968): A Manual of Standardized Terminology, Techniques, and Scoring for Sleep Stages of Human Subjects. Washington DC, Department of Health, Education, and Welfare
21. Schenck CS, Mahowald MW, Kim SW, O'Connor KA, Hurwitz TD (1992): Prominent eye movements during NREM sleep and REM sleep behavior disorder associated with fluoxetine treatment of depression and obsessive-compulsive disorder. Sleep 15:226-235
22. Sheehan DV, Claycomb JB, Kouretas N (1980): Monoamine oxidase inhibitors: Prescription and patient management. Int J Psychiatr 10(2):99-121
23. Spitzer RL, Williams JW, Gibbon M (1987): Structured Clinical Behavior for DSM-III-R. New York, Biometrics Research Division, New York State Psychiatric Institute
24. Stark P, Hardison CD (1985): A review of multicenter controlled studies of fluoxetine vs imipramine and placebo in outpatients with major depressive disorder. J Clin Psychiatr 46(3, Sect. 2):53-58
25. Ware JC (1983): Tricyclic antidepressants in the treatment of insomnia. J Clin Psychiatr 44(9, Sect 2):25-28
26. Wernicke JF (1985): The side-effect profile and safety of fluoxetine. J Clin Psychiatr 46(3, Sect. 2):59-67
27. Westheimer R, Klawans HL (1974): The role of serotonin in the pathophysiology of myoclonic seizures associated with acute imipramine toxicity. Neurology 24:1175-1177
28. Wong DT, Horng JS, Bymaster FP, Hauser KL, Molloy BB (1974): A selective inhibitor of serotonin uptake. Lilly 110140, 3-(p-trifluoromethylphenoxy)-N-methyl-3-phenylpropylamine. Life Sci 15:471-479